In particular, in these tumor cells, PrPC confers resistance of both P-glycoprotein (P-gp)-related and P-gp-non related drugs, which is accompanied by decreased accumulation and increased releasing amount of adriamycin in PrPC-overexpressing cells. This evidence concerns the gene PGP and neoplasm.